Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
ATTR amyloidosis is a rare, progressive and fatal disease that occurs when there is a buildup of abnormal (misfolded) transthyretin protein in the body's tissues and/or organs. Most commonly it affects the peripheral nerves, heart, intestinal tract, eyes and kidneys. The progressive accumulation of amyloid deposits in the nerves leads to sensory, motor and autonomic dysfunction often having debilitating effects on multiple aspects of a patient's life.
"We are proud to establish the Janice Wiesman Young Investigator Grant program, an important initiative to help increase our understanding of transthyretin amyloidosis and, ultimately, to better serve patients and families living with this devastating rare disease," said
"As Janice's husband, I saw first-hand how much her work in the amyloid community meant to her, not only professionally, in her role as a neurologist with the Amyloidosis Center at
Researchers at eligible academic or nonprofit institutions in the
March is Amyloidosis Awareness Month, an opportunity to drive attention to the symptoms, diagnosis and treatment of amyloidosis. During this month, patient organizations across the country and around the world will hold awareness-raising activities to bring attention to this debilitating, rare disease.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-establishes-new-grant-program-to-advance-research-and-understanding-of-transthyretin-amyloidosis-301236923.html
Ionis Pharmaceuticals Investor Contact: D. Wade Walke, Ph.D., Vice President, Investor Relations, 760-603-2741, Ionis Pharmaceuticals Media Contact: Roslyn Patterson, Vice President, Marketing and Communications, 760-603-4679